Risk factors, incidence and long-term outcomes of premature infants with retinopathy in a single tertiary clinic
Premature infants with retinopathy
Keywords:Bevacizumab, refractive result, retinopathy of prematurity
Objective: The aim of this study is to evaluate the risk factors of patients with retinopathy of prematurity (ROP) in a single tertiary clinic and to present the long-term refractive results of the patients who were treated.
Methods: Premature infants referred to Yeni Yüzyil University hospital or followed in the Neonatal Intensive Care Unit (NICU) of Yeni Yüzyil University hospital between 2017 and 2020 were evaluated retrospectively. In this study, patients were evaluated in three groups according to their gestational weeks (<28 gw, 29-32 gw, >32 gw). According to the Early Treatment Retinopathy Cooperative Group (ETROP) study, treatment was recommended for the infants with Type 1 ROP. Spherical equivalent (SEQ), cylindrical and spherical values of the treated cases were recorded at all follow-ups.
Results: A total of 646 premature babies born before 38 weeks were recorded between 2017 and 2020. 102 infants (15.7%) in group 1, 320 infants (49.53%) in group 2, and 224 infants (34.6%) in group 3 were examined. Among all infants, 18 eyes (1.39%) of 9 infants were treated with only one intravitreal injection of bevacizumab (0.025 ml/0.625 mg). The mean SE and spherical values decreased over time at the 3rd, 6th and 12th month follow-ups.
Conclusion: ROP can be controlled with an appropriate and effective treatment. Intravitreal injection of bevacizumab is a highly effective treatment option for type 1 ROP disease and Aggressive Posterior ROP. Long-term studies involving more patients are needed to evaluate the effect of treatment options on refractive outcome.
Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: I. Preliminary report. Am J Ophthalmol. 1942; 25:203–4.
The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102(8):1130e1134
Bas AY, Demirel N, Koc E, Ulubas Isik D, Hirfanoglu İM, Tunc T. Incidence, risk factors and severity of retinopathy of prematurity in Turkey (TR-ROP study): a prospective, multicentre study in 69 neonatal intensive care units. Br J Ophthalmol. 2018;102(12):1711-6.
Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP). A randomized, controlled trial. I: primary outcomes. Pediatrics. 2000; 105:295–310
Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of pre- maturity and risk factors: a prospective cohort study. BMC Pediatr. 2005; 5:18.
Dutta S, Narang S, Narang A, Dogra M, Gupta A. Risk factors of threshold retinopathy of prematurity. Indian Pediatr. 2004;41: 665– 71
Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117:572–6.
International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123:991–9
Holmström G, Hellström A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Evaluation of new guidelines for ROP screening in Sweden using SWEDROP - a national quality register. Acta Ophthalmol 2015; 93:265–8.
Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of
retinopathy of prematurity: Findings from the Early Treatment for Retinopathy of Prematurity Study. Pediatrics. 2005;116(1):15-23.
Öner A, Özkırış A, Güneş T, Karaküçük S, Erkılıç K, Çetin N. Retinopathy of prematurity: results of 2 years follow up. Erciyes Med J. 2005;27(3):104-9.
Kulaçoğlu DN, Sertöz AD, Ateş O, Baykal O. Prematüre retinopatisinde risk faktörleri ve tarama sonuçları. Ret Vit. 2005; 13:33-7.
Özalp HG. Trisomy 18 With Multiple Congenital Anomalies: A Rare Case Report. J Clin Tri Exp Invest. 2022; 1(1): 28-31.
Sarikabadayi YU, Aydemir O, Ozen ZT, Aydemir C, Tok L, Oguz SS et al. Screening for retinopathy of prematurity in a large tertiary neonatal intensive care unit in Turkey: frequency and risk factors. Ophthalmic Epidemiol. 2011;18(6):269-74.
Akman I, Demirel U, Yenice O, Ilerisoy H, Kazokoğlu H, Ozek E. Screening criteria for retinopathy of prematurity in developing coun- tries. Eur J Ophthalmol. 2010;20(5):931-37.
Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment de- spite confluent laser photocoagulation. Am J Ophthalmol. 2013; 155:159–64
Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS 2010; 14:2–3.
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-15
Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity -27-month follow-up results- from Turkey. Graefes Arch Clin Exp Ophthalmol 2015; 253:1677– 83.
Kang HG, Kim TY, Han J, Han SH. Refractive outcomes of 4-year- old children after intravitreal anti-vascular endothelial growth factor versus laser photocoagulation for retinopathy of prematu- rity. Korean J Ophthalmol 2019; 33:272–8.
Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al; BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014; 132:1327–33.
Kabatas EU, Kurtul BE, Altiaylik Ozer P, Kabatas N. Compari- son of Intravitreal Bevacizumab, Intravitreal Ranibizumab and laser photocoagulation for treat- ment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res 2017; 42: 1054–58.
How to Cite
Copyright (c) 2022 The Injector
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.